has provided consultation to Eisai, Biogen, Lilly, Roche, Genentech, Bolden, Novo Nordisk, Prothena, Acumen Pharmaceuticals, Labcorp, Alector, Corium, Kisbee, Neurophet, Icometrix and AbbVie
GLP-1 RA-based therapy has introduced a new era in the treatment of overweight and obesity, which is reflected in numerous clinical trials and patient-reported outcomes, highlighting its efficacy and safety profile (Kushner et al
The emphasis on personalized medicine is especially pivotal, allowing for customized GLP-1 formulations tailored to individual patient needs
In short: healthy weight loss requires sufficient calories, adequate protein, and mechanical stimulus
Important: Wegovy is NOT FDA-approved for sleep apneathat approval went to Zepbound (tirzepatide) in December 2024